ACET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Adicet Bio Inc (ACET) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak technical indicators, no recent positive news catalysts, and poor financial performance. While analysts maintain a Buy rating, the recent reverse stock split and lack of significant trading trends suggest caution. The investor should consider waiting for stronger signals or better financial performance before investing.
The technical indicators for ACET are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 30.22, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 6.585), with resistance levels at R1: 8.185 and R2: 8.679. Overall, the technical outlook suggests a weak price trend.
Analysts maintain a Buy rating with a significant price target increase from H.C. Wainwright to $50, reflecting optimism about the company's potential. However, this is primarily due to the reverse stock split.
The stock recently underwent a reverse stock split to maintain NASDAQ listing requirements, which can indicate financial instability. Additionally, there are no recent news catalysts, hedge fund or insider activity, or congress trading data to suggest positive sentiment.
Adicet Bio's Q3 2025 financials show no revenue growth (0% YoY), a net income decline of -11.88% YoY to -$26.856 million, and a drop in EPS by -12.10% YoY to -4.72. These figures indicate poor financial health and lack of profitability.
Analysts maintain a Buy rating. H.C. Wainwright raised the price target to $50 from $9, and Canaccord adjusted the target to $18 from $128 due to the reverse stock split. Despite the Buy ratings, the adjustments are largely technical and not based on improved fundamentals.
